tbuckley/cabot-search huggingface dataset:
Time Is Brain and Spine—Reply
Authors: Roos M. van der Vuurst de Vries, Rogier Q. Hintzen
Journal: JAMA Neurology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
GROWTH AND RE-INTERVENTION OF RESIDUAL AORTIC ARCH AND DESCENDING AORTA AFTER TYPE A DISSECTION REPAIR
Authors: Domenico Calcaterra, Truls Myrmel, Alan Braverman, Takeyoshi Ota, Reed Pyeritz, Maral Ouzounian, Clayton Allen Kaiser, Marc Schermerhorn, Derek Brinster, Anil Bhan, Daniel Montgomery, Anthony Estrera, Jean Bismuth, Kim Eagle, Eric Isselbacher, Christoph Nienaber, Kevin Harris
Journal: Journal of the American College of Cardiology (2019)
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND ITS RISK FACTORS ARE ASSOCIATED WITH IMPAIRED COGNITIONIN OLDER ADULTS
Authors: Xue Qiao Zhao, Yunli Xing, Ying Sun, Michael Chen, Xiting Wu, Dai Zhang, Wei Huang, Yining Cui, Qiqi Yang, Hongwei Li
Journal: Journal of the American College of Cardiology (2019)
Effect of Glibornuride on Diabetic Control and Glucose Tolerance<sup>1</sup>
Authors: C J Fox, B J Hay, S L Judd, P H Sönksen
Journal: Journal of the Royal Society of Medicine (1978)

Sulphonylureas are still prescribed in increasing amounts in the UK (Statistics and Research Division, DHSS, personal communication) despite the suggestion from the Universities Group Diabetic Program trial (1970) that their use may be associated with an increased risk of cardiovascular death. Tolbutamide, the first of the sulphonylureas still in common use, has a half-life of only five hours and is usually taken in two or three daily doses. The half-life of chlorpropamide, which is not metabolized by the liver, is 36 hours and its use may lead to prolonged hypoglycaemia particularly in the elderly and those with renal impairment (Schen & Benaroya 1976). Glibornuride has been widely used on the continent for several years, but only recently became available in the UK. This compound is rapidly absorbed from the gut and inactivated by the liver to give a half-life of eight hours. A trial was set up to examine the clinical acceptability of glibornuride and to confirm that like other sulphonylureas it leads to an increase in insulin secretion (Perkins et al. 1977).
CLINICAL OUTCOMES OF NEWER-GENERATION VERSUS SECOND-GENERATION DRUG-ELUTING STENT IMPLANTATION IN PATIENTS WITH CORONARY ARTERY DISEASE: RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
Authors: Yuki Sato, Shota Okuno, Takayuki Ishihara, Osamu Iida, Mitsutoshi Asai, Masaharu Masuda, Shin Okamoto, Kiyonori Nanto, Takashi Kanda, Takuya Tsujimura, Yasuhiro Matsuda, Hiroyuki Kawai, Aki Tsuji, Yosuke Hata, Hiroyuki Uematsu, Naoko Higashino, Taku Toyoshima, Toshiaki Mano
Journal: Journal of the American College of Cardiology (2019)
NO DIFFERENCES IN REST MYOCARDIAL BLOOD FLOW IN STUNNED AND HIBERNATING MYOCARDIUM: INSIGHTS FROM POSITRON EMISSION TOMOGRAPHY MYOCARDIAL PERFUSION IMAGING INTO THE PATHOPHYSIOLOGY OF ISCHEMIC CARDIOMYOPATHY
Authors: Dominik C. Benz, Oliver Gaemperli, Philipp A. Kaufmann, Ronny Buechel
Journal: Journal of the American College of Cardiology (2019)
The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial
Authors: Charalampos Loutradis, Pantelis A. Sarafidis, Robert Ekart, Christodoulos Papadopoulos, Vasileios Sachpekidis, Maria Eleni Alexandrou, Dorothea Papadopoulou, Giorgos Efstratiadis, Aikaterini Papagianni, Gerard London, Carmine Zoccali
Journal: Kidney International (2019)
OUTCOMES OF CATHETER ABLATION FOR ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
Authors: Lohit Garg, Syed Rafay Ali Sabzwari, Ghulam Akbar, Hiwot Ayele, Sahil Agrawal, Manyoo Agarwal, Jeffrey Gordon, Raman Dusaj, Talha Nazir, Babak Bozorgnia, Matthew Martinez
Journal: Journal of the American College of Cardiology (2019)
MACHINE LEARNING PREDICTED FILLING PRESSURES FROM LUNG DOPPLER SIGNALS (LDS) PROVIDE A NOVEL METHOD TO MONITOR PULMONARY CONGESTION IN CONGESTIVE HEART FAILURE PATIENTS
Authors: Muhammad Ashraf, Yasir Abdul Ghaffar, Chetan Virmani, Muhammad J. Khalil, Lan Hu, Sirish Shrestha, Marco Piccirilli, Christopher Bianco, Partho Sengupta
Journal: Journal of the American College of Cardiology (2019)
DIASTOLIC FUNCTION IMPROVEMENT PREDICTS MORTALITY AND MACE IN PATIENTS WITH CHRONIC HEART FAILURE TREATED WITH RESYNCHRONIZATION THERAPY
Authors: Gabriele De Masi De Luca, Pietro Palmisano, Sergio De Blasi, Simonetta Longo, Francesca Barba, Alessandro Guido, Paola Papadia, Michele Accogli
Journal: Journal of the American College of Cardiology (2019)
Abstract 379: Effects of Microgravity on Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Structure and Function
Authors: Alexa Wnorowski, Arun Sharma, Haodong Chen, Haodi Wu, Ning-Yi Shao, Jared M Churko, Elena Matsa, Stefanie Countryman, Kathleen Rubins, Sean M Wu, Peter H Lee, Joseph C Wu
Journal: Circulation Research (2018)

With extended stays aboard the International Space Station (ISS) becoming commonplace as humanity prepares for exploration-class space missions, the need to better understand the effects of cardiac function during spaceflight is critical. However, primary human heart tissues, which would be useful for in vitro studies on heart function, are difficult to obtain and maintain. As a model system, we utilized cardiomyocytes (CMs) derived from human induced pluripotent stem cells (hiPSCs) to study the effects of microgravity on human cardiac function and gene expression at the cellular level. We derived hiPSCs from three healthy volunteers and produced hiPSC-CMs using a high-efficiency hiPSC-CM differentiation protocol. We cultured hiPSC-CMs in a microgravity environment aboard the ISS for approximately one month, during which weekly media changes were conducted. We analyzed the gene expression, structure, and function of flight, post-flight, and ground control hiPSC-CM samples using RNA-sequencing, immunofluorescence, calcium imaging, and contractility assessment. Exposure to microgravity on the ISS resulted in decreased contractile velocity and calcium recycling in the hiPSC-CM, along with increased beating irregularities. RNA-sequencing analysis demonstrated that there were 2635 genes differentially expressed with p≤0.05 between flight, post-flight, and ground control samples. These included genes involved in metabolism, DNA/RNA modification, and molecular transport, indicating that these pathways may be permanently altered by long-term space flight . This study represents the first time that hiPSC technology has been used to study the effects of microgravity on human cardiac function and is the first to demonstrate that microgravity affects human heart function on the cellular level.
Abstract 21256: Cardiac ECM Environment Improves iPSC-Derived Cardiomyocyte Differentiation
Authors: Andras Czirok, Dona G Isai, Sheeja Rajasingh, Mike Filla, Rajasingh Johnson
Journal: Circulation (2017)

Introduction: Generation of induced pluripotent stem cells (iPSCs) and their differentiation into cardiomyocytes (CMCs) have created exciting possibilities in cardiac medicine. However, the long-term impact of iPSC-derived CMC implantation on cardiac function remains elusive. After the first month following injection, only less than 10% of the implanted cells remain alive. In contrast, during development mesodermal precursors differentiate into a functional myocardium without substantial cell loss. Hypothesis: The poor survival of iPSC-derived CMCs is mainly attributable to the lack of evolutionarily determined microenvironment in which the normal differentiation process takes place. Thus, we hypothesize that the embryonic or adult heart-derived extracellular matrix (ECM) provides a better culture environment for CMC differentiation. Methods: We utilized a highly efficient, viral-free combination of DNA and mRNA transcription factor approach to generate iPSCs and functional CMCs from adult human cells. To analyze CMC contractility, we recorded cultures using both time-lapse and high frame-rate video microscopy. ECM from adult and embryonic chicken hearts was extracted using a high salt/urea protocol, and lyofilized. iPSCs were grown on a variety of substrates, including rehydrated cardiac ECM or electrospinned films. The quality of differentiation was characterized by molecular markers, electron microscopy and tracking beat frequencies. Results: Heart ECM extracts provide a supportive environment for CMC differentiation. When grown on ECM extracted from adult chicken hearts, the maturation of iPSCs-derived cardiomyocytes exceeds those that were cultured using matrigel environments. For example, in vitro beat rates are higher on heart ECM (Figure, red symbols) than on matrigel (black). Conclusions: Culture environments containing heart-derived matrix is a promising avenue to improve the quality of iPSC-derived cardiomyocytes.
Palliative care in mesothelioma: Are current services RESPECT-able enough?
Authors: Neelam Kumar, Doraid Alrifai, Ioannis Psallidas
Journal: Thorax (2019)

Malignant pleural mesothelioma (MPM) remains a devastating disease with a poor prognosis; median survival ranges from just 8 to 14 months from diagnosis.1 The incidence is the highest in the UK and Australia and while this is expected to peak by 2020, the global incidence is predicted to increase for several decades particularly in emerging economies. Treatment options remain limited. Chemotherapy using third-generation antifolate agents is the only treatment modality that has been shown to improve survival in MPM.2 Standard first-line treatment is combination pemetrexed and cisplatin (or carboplatin), however response rates to these regimens are low. An evaluation of over 1700 patients who received pemetrexed with either cisplatin or carboplatin demonstrated response rates of 26.3% and 21.7%, respectively.3 Surgical management is controversial with a lack of robust randomised trial data. Novel treatments are however on the horizon. The genomic era has led to the early development of precision therapies, and as with several other cancers, immunotherapy may hold promise.4 

Alongside a paucity of current effective treatments, patients with MPM are also subject to a high symptom burden. In a study of 495 patients,5 92% reported three or more symptoms at diagnosis with fatigue (94%), dyspnoea (89%), chest pain (85%), appetite loss (87%) and cough (75%) being the most common. The psychological burden of a diagnosis of MPM can be equally distressing with patients reporting feelings of uncertainty and lack of control.6 Carers of patients with MPM similarly report an emotional and physical toll.7 Arguably, MPM is therefore the archetypal disease necessitating effective palliative care, defined by the WHO as ‘an approach that improves the quality of life of patients and their families facing life-threatening illness, through the prevention and relief of suffering by early identification and impeccable assessment and treatment of pain …
Abstract 546: GJA1-20k Protects the Heart From Ischemic Injury by Inducing Mitochondrial Biogenesis and Metabolic Quiescence
Authors: Wassim A Basheer, Ying Fu, Shaohua Xiao, TingTing Hong, Robin M Shaw
Journal: Circulation Research (2018)

Connexin 43 (Cx43) is a cell-cell communication gap junction protein that is encoded by the GJA1 gene and is expressed in all organ systems. It was recently found that the GJA1 mRNA undergoes alternative translation to generate N-terminally truncated isoforms, of which GJA1-20k is the most abundant. We have recently identified that GJA1-20k has a strong tropism for mitochondria and that GJA1-20k overexpression is sufficient to rescue mitochondrial localization to the cell periphery, limiting organelle network collapse upon exposure to oxidative stress. Given the protective role of GJA1-20k on mitochondrial network and the importance of preserving mitochondrial integrity in preventing cardiac ischemic injury, we therefore asked the question whether exogenous GJA1-20k can increase myocardial survival when subjected to stress. Using high resolution confocal imaging, we find that H 2 O 2 -induced oxidative stress in cardiomyocytes causes an upregulation of GJA1-20k independent of full length Cx43 expression. Furthermore, we find that GJA1-20k is upregulated and preferentially enriched in mitochondria after acute ischemia/reperfusion injury in isolated mouse hearts. We also find that exogenous GJA1-20k, when delivered by adenovirus to isolated adult mouse cardiomyocytes, was sufficient to improve cell survival and viability during H 2 O 2 -induced oxidative stress. When delivered in vivo using an Adeno-associated virus serotype 9 (AAV9), GJA1-20k exhibited potent cardioprotective effects by reducing ischemic injury size in a mouse model of myocardial infarction. AAV9-mediated gene transfer of GJA1-20k also resulted in increased cardiac mitochondrial content as observed by electron microscopy. Yet 20k-increased mitochondrial content in cardiomyocytes is associated with reduced mitochondrial membrane potential as well as respiration as measured by Seahorse assay, indicating a quiescent metabolic state resistant to stress. In conclusion, we have identified GJA1-20k as a stress response protein that increases mitochondrial biogenesis and reduces metabolic reactivity, providing powerful cardioprotection against ischemic insults.
Quick Uptakes
Authors: Rita Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DETERMINANTS OF TRUNK MUSCLE SIZE DECREASE IN PATIENTS WITH ACUTE AORTIC DISSECTION
Authors: Keiichi Tsuchida, Kenji Nakano, Norihito Oyanagi, Rie Akagawa, Mitsuo Ishizuka, Takahiro Hakamata, Komei Tanaka, Yukio Hosaka, Kazuyoshi Takahashi, Hirotaka Oda
Journal: Journal of the American College of Cardiology (2019)
Regular review: Management of patients who deliberately harm themselves
Authors: G. Isacsson
Journal: BMJ (2001)

Deliberate self harm is a behaviour not an illness. It is defined as any act by an individual with the intent of harming himself or herself physically and which may result in some harm. Deliberate self harm has also been called “attempted suicide” or “parasuicide.” Although attempted suicide should be restricted to cases where a fatal intent can be assumed, these terms are often used synonymously. Suicide is the subcategory with a fatal outcome.

#### Summary points

Patients who deliberately harm themselves should be assessed as comprehensively and thoroughly as possible, including the risk for suicide

A multidisciplinary team approach to assessment and management is optimal

A psychiatrist should be involved in the evaluation

Management should be individualised on the basis of the assessment; mostly treatment for associated psychiatric disorders and assistance with precipitating circumstances

Patients accepting offers for help should be followed up quickly

Typically 10-30 per 100 000 people commit suicide annually. Deliberate self harm that is non-fatal may be 10-20 times more frequent. Both fatal and non-fatal deliberate self harm constitute considerable public health problems regarding both individual suffering and costs to society.

The motivations behind acts of deliberate self harm vary. One motivation may be a wish to die. Deliberate self harm may also constitute a more or less dysfunctional way of achieving wanted changes of life—for example, escape, attention, manipulation of others. The intent in each person is complex and ambivalent. Although some aspects of suicidal behaviour might be interpreted as rational, the behaviour is contrary to basic biological principles of survival. Therefore it may be postulated that some link in the individual's perception, cognitive and emotional processing, and behaviour is disordered—that is, a psychiatric disorder. This is corroborated by empirical studies.

In a two year Swedish study of 812 consecutive patients who had deliberately harmed themselves, 11% …
EPTIFIBATIDE INDUCED PROFOUND THROMBOCYTOPENIA: A NEW APPROACH TO MANAGEMENT USING INTRAVENOUS IMMUNOGLOBULIN AND HIGH DOSE STEROIDS
Authors: Monali Patel, Giselle Suero-Abreu, Renjit Thomas, Ahmad Alkhalil, Shashank Jain, Anoshia Raza, Christine Gerula, James Maher, Alfonso Waller, Marc Klapholz
Journal: Journal of the American College of Cardiology (2019)
Abstract 117: Regulation of Cardiac Mitochondrial Function by Chaperone Mediated Autophagy
Authors: Yun Chen, Jaehoon Lee, Min Zheng, Victor Paulino, Christian Garcia, Julio M Matute, Hong Li, Nina Kaludercic, Edward Owusu-Ansah, Ana Maria Cuervo, Richard N Kitsis
Journal: Circulation Research (2018)

Macroautophagy is required for normal cardiac function. Chaperone mediated autophagy (CMA) is distinct in that substrates are transported to lysosomes in complex with Hsc70, rather than within autophagosomes; restricted to cytoplasmic proteins; and selectively marked with a CMA-targeting motif. The role of CMA in the heart has not been assessed. We determined that CMA is induced in the heart by pressure overload with kinetics that differ markedly from those of macroautophagy in response to the same stimulus. In CMA, cargo is imported into the lysosome by LAMP2A, which is necessary, specific, and rate-limiting for this process. Accordingly, we created knockout mice lacking LAMP2A in cardiomyocytes to inactivate CMA specifically in those cells. Unexpectedly, these mice exhibited resistance to stress-induced cardiac dysfunction in both pressure overload and myocardial infarction models. Functional assessment of cardiac mitochondria from L2AKO mice and MEFs exhibited increased rates of O 2 consumption and ATP generation. Mitochondrial proteomics showed increased levels of ATP5L, a component of mitochondrial Complex V (ATP synthase). Overexpression of ATP5L phenocopied LAMP2A KO with respect to augmentation of mitochondrial function. Conversely, knockdown of ATP5L reversed increases in mitochondrial function resulting from L2AKO. We showed that ATP5L, which possesses a KFERQ motif, is a bona fide CMA substrate as it interacts with Hsc70 in a KFERQ-dependent manner; and localizes to lyososmes in a LAMP2A-dependent manner when CMA is induced. ATP5L is thought to mediate oligomerization of Complex V to enhance ATP production. In fact, we observed increases in complex V oligomerization in L2A KO mouse hearts in both basal and TAC-induced states. In summary, cardiomyocyte-specific inhibition of CMA, which renders mice resistant to stress-induced cardiac dysfunction, augments cardiac mitochondrial function through accumulation of ATP5L. Conversely, activation of CMA by cardiac stress may function as a new pathway to heart failure.
PEDIATRICS LABORATORY RESEARCH
Authors: M. S. Brassesco, E. T. Valera, J. A. Pezuk, A. G. Morales, J. C. Oliveira, K. Umezawa, E. M. Rego, G. C. Carlotti, C. A. Scrideli, L. G. Tone, J.-i. Adachi, T. Suzuki, T. Yanagisawa, K. Fukuoka, K. Mishima, K. Wakiya, M. Matsutani, R. Nishikawa, A. Fernandez-L, M. Squatrito, P. Northcott, E. C. Holland, M. D. Taylor, Z. Nahle, A. M. Kenney, D. M. Ashley, A. Muscat, L. Gordon, L. Rigby, D. Birks, N. Foreman, E. Algar, L. K. Donovan, N. Potter, T. Warr, G. Pilkington, A. Erdreich-Epstein, H. Zhou, X. Ren, T. B. Davidson, M. Schur, L. Ji, R. Sposto, S. Asgharzadeh, L. Hiddingh, V. Caretti, E. Hulleman, G.-J. L. Kaspers, W. P. Vandertop, D. P. Noske, T. Wurdinger, V. Caretti, L. Hiddingh, T. Lagerweij, P. W. Koken, E. Hulleman, W. P. Vandertop, D. P. Noske, G. G. Kaspers, T. Wurdinger, E. E. Bar, K. Schreck, C. G. Eberhart, D. A. Largaespada, J. D. Larson, F. J. Rodriquez, A. M. Demer, A. L. Sarver, A. Dubuc, R. B. Jenkins, A. J. Dupuy, N. G. Copeland, N. A. Jenkins, M. A. Taylor, M. Monje, M. E. Freret, P. A. Beachy, V. Caretti, T. Lagerweij, M. H. Jansen, P. W. Vandertop, D. P. Noske, G. G. Kaspers, T. Wurdinger, K. Dorris, M. Sobo, E. Panditharatna, C. Liu, M.-O. Kim, L. Miles, S. Goldman, S. Gardner, C. Stevenson, T. Maugans, M. Fouladi, R. Drissi, D. W. Fults, M. Mumert, C. A. Pedone, X. Wu, P. A. Northcott, M. D. Taylor, A. M. Saratsis, S. Magge, B. Rood, A. Hill, J. Nazarian, V. Caretti, M. H. Jansen, D. G. van Vuurden, E. Hulleman, T. Lagerweij, M. Bugiani, D. P. Noske, P. W. Vandertop, P. Wesseling, T. Wurdinger, G. J. Kaspers, V. Gopalakrishnan, C. Das, M. Gireud, P. Taylor, A. Singh, D. Lee, K. Aldape, G. Fuller, L. Ji, J. Fangusaro, V. Rajaram, S. Goldman, C. Eberhart, V. Gopalakrishnan, P. Taylor, J. Fangusaro, V. Rajaram, S. Goldman
Journal: Neuro-Oncology (2011)
Canada: tobacco companies must pay C$16bn to Quebec smokers, appeal court rules
Authors: Owen Dyer
Journal: BMJ (2019)

Quebec’s Court of Appeal has upheld a landmark 2015 judgment ordering three tobacco companies to pay C$16bn (£9.1bn; €10.6bn; US$12bn) in damages to Quebec smokers.12

Imperial Tobacco, JTI-Macdonald, and Rothmans-Benson & Hedges won some minor procedural arguments but lost their appeal on all substantive grounds before Quebec’s highest court. Interest that has accrued during the appeal process will add more than a billion dollars to the payout in Canada’s biggest ever class action suit, which was first filed 21 years ago.

The three companies are expected to launch one final appeal, to Canada’s Supreme Court, which the plaintiffs’ lawyers hope could be completed in about a year. The companies also face several lawsuits from provinces looking to recoup decades of smoking related health expenditure.

The Quebec class action was notable not just for the size of the claims but for the novel arguments deployed …
18F-FLOURIDE POSITRON EMISSION TOMOGRAPHY MAGNETIC RESONANCE VERSUS POSITRON EMISSION TOMOGRAPHY COMPUTERISED TOMOGRAPHY IN VALVULAR AND CORONARY HEART DISEASE: A COMPARISON OF ATTENUATION CORRECTION METHODS
Authors: Jack Andrews, Gillian MacNaught, Alastair Moss, Mhairi K. Doris, Tania Pawade, Philip Adamson, Christophe Lucatelli, David Newby, Marc Dweck
Journal: Journal of the American College of Cardiology (2019)